NEWS RELEASE

Evolus to Participate in the Barclays Global Healthcare Conference

2/28/2023

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the Barclays Global Healthcare Conference in Miami Beach, Florida.

Event:	Barclays Global Healthcare Conference
Date:	Tuesday, March 14, 2023
Time:	2:35-3:00pm ET

An audio webcast of this event will be available on the investor relations section of Evolus' website at **www.evolus.com**. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at **www.evolus.com** and follow us on **LinkedIn**, **Twitter**, **Instagram** or **Facebook**.

Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: **david.erickson@evolus.com**

Media Contact:
Email: **media@evolus.com**

Source: Evolus